Business Context and Reporting Period
Company: BIOVIE INC. (BIVI)
Filing Type: Form 10-K (Annual Report)
Reporting Period: Fiscal Year Ended June 30, 2024
Business Overview: BioVie is a clinical-stage biopharmaceutical company developing therapies for neurological/neurodegenerative disorders (Alzheimer's, Parkinson's, Long COVID) and advanced liver disease (ascites). The company has no approved products and has never generated revenue.
Key Financial Metrics
| Metric | Year Ended June 30, 2024 | Year Ended June 30, 2023 |
|---|---|---|
| Net Loss | $(32.1) million | $(50.3) million |
| Net Loss Attributable to Common Stockholders | $(33.0) million | $(50.3) million |
| Total Operating Expenses | $(32.2) million | $(45.1) million |
| Research & Development (R&D) Expenses | $(23.1) million | $(33.3) million |
| Selling, General & Administrative (SG&A) | $(8.8) million | $(11.6) million |
| Cash and Cash Equivalents (End of Period) | $23.8 million | $19.5 million |
| Working Capital | $14.7 million | $19.5 million |
| Accumulated Deficit | $(334.2) million | $(301.2) million |
| Debt (Current Portion of Note Payable) | $5.7 million (net) | $9.1 million (net) |
Note: The company reported no revenue for either period. Interest income increased to $1.1 million in 2024 due to investments in U.S. Treasury Bills.
Material Changes vs. Prior Period
- Reduced Net Loss: Net loss decreased by approximately $17.3 million (34%) year-over-year, primarily driven by a $10.2 million reduction in R&D expenses and a $2.7 million reduction in SG&A.
- R&D Expense Drivers: The decrease in R&D was largely due to the completion of the pivotal Phase 3 Alzheimer's study and the Phase 2 Parkinson's study in the prior year, which reduced costs by approximately $13.8 million. This was partially offset by $3.6 million in new study planning and CMC expenses.
- SG&A Expense Drivers: Decreased primarily due to lower stock and cash compensation for executives/directors ($2.8 million) and reduced investor relations fees, offset slightly by higher legal and insurance costs.
- Other Income/Expense: Shifted from a net expense of $5.2 million in 2023 to net income of $59,000 in 2024. This was driven by a $3.3 million gain from the change in fair value of derivative liabilities and reduced interest expense.
- Liquidity: Cash and cash equivalents increased by $4.4 million, supported by net proceeds of approximately $27.8 million from equity issuances (including a March 2024 offering and ATM sales), partially offset by $10 million in debt repayments.
Guidance, Outlook, Risks, and Unusual Items
Outlook and Guidance
The company provides no specific financial guidance. Future operations depend on securing additional financing. Management expects to fund operations through equity sales, loans, or strategic transactions. The company raised approximately $3.0 million in a subsequent public offering in September 2024.
Management Commentary & Clinical Updates
- Alzheimer's Disease (Bezisterim/NE3107): The Phase 3 trial (NCT04669028) was underpowered due to the exclusion of 15 sites (approx. 50% of patients) following significant protocol deviations and suspected improprieties. While the trial did not meet primary endpoints statistically, the Per-Protocol population showed a descriptive signal of slowed cognitive loss and age deceleration. The company is exploring adaptive trial features or a new Phase 3 design.
- Parkinson's Disease: Phase 2 results were positive, showing statistically significant improvements in motor symptoms and non-motor symptoms. A new Phase 2 study for new-onset PD was submitted to the FDA in July 2024.
- Long COVID: Awarded up to $13.1 million in non-dilutive funding from the U.S. Department of Defense for a Phase 2 trial. The FDA authorized the IND in August 2024; trial commencement is expected in early 2025.
- Liver Disease (BIV201): Phase 2 data showed a 53% reduction in ascites fluid. The company is finalizing Phase 3 protocol designs following FDA guidance.
Risks and Contingencies
- Going Concern: The company has an accumulated deficit of $334.2 million and recurring losses. The auditor has raised substantial doubt about the company's ability to continue as a going concern without additional financing.
- Legal Proceedings: The company is subject to a consolidated securities class action lawsuit (In re BioVie Inc. Securities Litigation) alleging misrepresentations regarding the Phase 3 Alzheimer's trial. The company intends to defend vigorously but cannot predict the outcome. Insurance coverage has a $2 million deductible.
- Capital Needs: The company requires substantial additional capital to fund clinical trials and operations. Failure to raise funds could force the cessation of operations.
- Reverse Stock Split: A 1-for-10 reverse stock split was effected on August 6, 2024. The company cannot predict the effect on market price or liquidity.
Investor Verification Checklist
- Cash Runway: Verify the current cash balance and burn rate to assess the timeline before additional capital is required, given the "substantial doubt" going concern warning.
- Alzheimer's Trial Status: Confirm the FDA's response to the company's proposal for an adaptive trial or new Phase 3 design following the data integrity issues at 15 sites.
- Long COVID Funding: Monitor the disbursement schedule of the $13.1 million DOD grant and the actual start date of the Phase 2 trial.
- Legal Exposure: Track the progress of the securities class action lawsuit and any potential settlement costs exceeding the $2 million insurance deductible.
- Dilution Risk: Review the terms of the September 2024 offering and the existing ATM facility, noting the significant number of warrants and options outstanding that could dilute existing shareholders.